SGLT2 Inhibitors and Cardiovascular Outcomes

The focus of this program is on atherosclerotic cardiovascular disease, heart failure, and SGLT2 inhibitors and provides timely insights into implementing evidence-based treatment strategies. Darren McGuire, MD, MHSc summarizes the glycemic and non-glycemic effects of SGLT2 Inhibitors, their safety profile and recent clinical outcome trials. Cindy Lamendola MSN, ANP-BC, presents case studies that highlight the role of SGLT2 inhibitors in a non-diabetic patient with ASCVD and HF.
0.00